
IVERIC bio ISEE
Quartalsbericht 2023-Q1
hinzugefügt 10.05.2023
IVERIC bio Kurzfristige Verbindlichkeiten 2011-2026 | ISEE
Kurzfristige Verbindlichkeiten Jährlich IVERIC bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.6 M | 28.2 M | 25.1 M | 13 M | 13.2 M | 12.5 M | 65.9 M | 37.5 M | 19.8 M | 6.3 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 65.9 M | 6.3 M | 25.7 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
4.59 M | $ 0.89 | - | $ 6.54 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.2 | - | $ 3.68 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Edesa Biotech
EDSA
|
1.83 M | $ 15.9 | - | $ 50.8 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Exelixis
EXEL
|
406 M | $ 44.69 | - | $ 12.1 B | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Harmony Biosciences Holdings
HRMY
|
252 M | $ 31.05 | - | $ 1.79 B | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
3.98 M | $ 8.44 | - | $ 76.2 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Incyte Corporation
INCY
|
1.52 B | $ 99.1 | - | $ 19.3 B | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
InMed Pharmaceuticals
INM
|
2 M | $ 0.7 | - | $ 1.71 M | ||
|
INmune Bio
INMB
|
8.42 M | $ 1.33 | - | $ 32.9 M | ||
|
Innoviva
INVA
|
49.7 M | $ 23.05 | - | $ 1.55 B | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Jaguar Health
JAGX
|
40.7 M | $ 7.88 | - | $ 18.4 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
57.4 M | $ 26.67 | - | $ 1.44 B | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 2.98 | - | $ 4.91 M | ||
|
Krystal Biotech
KRYS
|
103 M | $ 259.95 | - | $ 7.52 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
37.1 M | $ 224.86 | - | $ 4.11 B | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Liquidia Corporation
LQDA
|
136 M | $ 38.15 | - | $ 3.28 B | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.05 | - | $ 433 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M |